Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Sarudbhava Formulations Private Limited currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 2 distinct examiners and 2 distinct art units. This distribution shows a level of diversification in the prosecution process, with 2 distinct examiners reviewing the company's applications. This spread means that the company's patenting success is subject to the review of different individuals.
NOTTINGHAM, KYLE GREGORY is the busiest examiner for the portfolio, currently overseeing 1 busiest examiner pending action. With 2 pending office actions in total, the workload is spread across these examiners. This means that no individual examiner has a majority of the active cases, which suggests a prosecution environment where different perspectives are applied to the company's innovations.
Practitioners should observe that the 2 distinct art units involved indicate that the company's innovations are being evaluated under different sets of technical criteria. The current volume of pending office actions indicates the level of activity. The spread across these examiners requires a strategy that accounts for different perspectives within the patent office, as each examiner may have unique interpretations of biotechnology patentability. Strategies for this portfolio are currently dependent on the specific requirements and tendencies of NOTTINGHAM, KYLE GREGORY.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NOTTINGHAM, KYLE GREGORY | 1 | 61.7% | +31.9% |
| RODRIGUEZ, RAYNA B | 1 | 33.6% | +19.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17774981 | APREMILAST LOW-DOSE TOPICAL PHARMACEUTICAL COMPOSITIONS | NOTTINGHAM, KYLE GREGORY | — |
| 16481257 | THERAPEUTIC TOPICAL COMPOSITIONS OF APREMILAST | RODRIGUEZ, RAYNA B | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17774981 | APREMILAST LOW-DOSE TOPICAL PHARMACEUTICAL COMPOSITIONS | NOTTINGHAM, KYLE GREGORY | 1621 | §103 | Non-Final OA | — | Pending | May 06, 2022 |
| 16481257 | THERAPEUTIC TOPICAL COMPOSITIONS OF APREMILAST | RODRIGUEZ, RAYNA B | 1628 | §103 | Non-Final OA | — | Pending | Jul 26, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSarudbhava Formulations Private Limited has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Kyle Gregory Nottingham has the most, with 1 of Sarudbhava Formulations Private Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
